Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia
Status:
Completed
Trial end date:
2020-03-16
Target enrollment:
Participant gender:
Summary
This was a study of the safety and efficacy of ceftobiprole medocaril compared with
intravenous (IV) standard-of-care cephalosporin treatment with or without vancomycin in
pediatric patients with either hospital-acquired bacterial pneumonia (HAP) or
community-acquired bacterial pneumonia (CAP) requiring hospitalization, and requiring
intravenous (IV) antibiotic therapy.